Robute Guilliman and Lion El'Jonson are the only two loyalist Primarchs around and they need some back-up from their brothers ...

According to MarketBeat, Corvus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $12.38. 10 Stocks to Sell NOW! 3 Stocks to DOUBLE This Year ...

If you want more great stories of action, courage, and tragedy, we have another guide to the best Warhammer 40k books. Our guides to the Warhammer 40k factions are packed with lore. If you’re only ...

H.C. Wainwright launched its coverage of eczema drug developer Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy recommendation and an $11 per share target on Thursday, despite an over 38% drop ...

Corvus Pharmaceuticals (NASDAQ:CRVS) lost ~34% in the premarket on Wednesday after the company announced early results from a Phase 1 trial for its lead asset, soquelitinib, in patients with ...

The Corvus Cabal worships the Great Gatherer by taking treasures from the victims of their ambushes and assassinations. They believe the Archaon is an avatar of their god and as such, seek to gain his ...

Cavill is a known Warhammer 40K fan by now and has talked about his passion for the universe extensively, but for those who weren’t familiar with his hobby, his latest Instagram post about the ...

Corvus Pharmaceuticals shares interim Phase 1 trial data showing promising results for soquelitinib in treating moderate to severe atopic dermatitis.

It is a well-known fact among many that tabletop games are pretty expensive, especially among Warhammer 40K fans. Models of the famed wargame are almost exorbitantly expensive, with army boxes ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 ...